20/20 Onsite Expands Mobile Vision Fleet, Strengthening Nationwide Reach and Clinical Trial Support Capacity

BOSTON--(BUSINESS WIRE)--20/20 Onsite, the leading provider of point-of-need ophthalmic services for clinical trials, announces the deployment of its latest mobile vision clinic, bringing its fleet to 16 units, including a mix of mobile clinics, pods, and suites. The new unit hit the road in early May and is now fully operational, enabling 20/20 Onsite to support a higher tempo of decentralized and hybrid clinical trials nationwide.

We can confidently say we’re built to provide advanced ophthalmic support to trials with dozens of sites across multiple geographic regions.

Share

This milestone reinforces 20/20 Onsite’s ability to scale with sponsors, CROs, and sites, offering advanced, patient-centric ophthalmic services at trial sites nationwide.

“Most people don’t realize just how expansive our fleet has become,” said Sonali Bloom, CEO at 20/20 Onsite. “With 16 units now in operation and more coming due to high demand, we can get to a patient anywhere in the country in 2 days or less. We can confidently say we’re built to provide advanced ophthalmic support to trials with dozens of sites across multiple geographic regions.”

20/20 Onsite has supported over 45 clinical trials, conducted 85,000+ point-of-need patient visits, and continues to position itself to meet the rising demand for ocular endpoint protection in hybrid or decentralized trials.

The new unit is already deployed on active trials and staffed with certified technicians and optometrists equipped to deliver best-in-class imaging and eye assessments. As the 20/20 Onsite fleet expands, it ensures trial continuity by simplifying patient logistics and reducing travel burden, making it easier for sponsors to retain participants, meet study timelines, and protect ocular endpoints.

About 20/20 Onsite

20/20 Onsite is a clinical trial solutions company specializing in quality ocular endpoint protection through its nationwide point-of-need fleet. By bringing advanced ophthalmic assessments directly to clinical trial participants—whether at sites, homes, or community locations—20/20 Onsite makes it easier for sponsors, CROs, and sites to collect critical data, reduce patient burden, and improve trial outcomes.

20/20 Onsite has supported over 45 clinical trials, served more than 85,000 patients, achieved 100% of screening timelines, and consistently delivered patient Net Promoter Scores (NPS) above 95.

To learn more about how 20/20 Onsite delivers quality ocular endpoint protection at scale, visit www.2020onsite.com.